Stifel Nicolaus Upgrades Tandem Diabetes Care (NASDAQ:TNDM) to Buy

Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) was upgraded by research analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating in a research note issued on Wednesday, MarketBeat reports. The firm presently has a $26.00 price objective on the medical device company’s stock, up from their previous price objective of $22.00. Stifel Nicolaus‘s price target suggests a potential upside of 52.40% from the company’s current price.

TNDM has been the topic of several other reports. Wells Fargo & Company lowered their price objective on shares of Tandem Diabetes Care from $27.00 to $25.00 and set an “overweight” rating on the stock in a research report on Friday, November 6th. Truist Financial dropped their price objective on shares of Tandem Diabetes Care from $31.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, September 24th. UBS Group initiated coverage on shares of Tandem Diabetes Care in a report on Tuesday, July 28th. They issued a “neutral” rating and a $18.00 target price for the company. Barclays increased their target price on shares of Tandem Diabetes Care from $18.00 to $20.00 and gave the stock an “equal weight” rating in a research note on Friday, November 6th. Finally, Citigroup lowered their price target on Tandem Diabetes Care from $24.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, September 30th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Tandem Diabetes Care presently has a consensus rating of “Hold” and a consensus target price of $27.39.

View Our Latest Analysis on TNDM

Tandem Diabetes Care Price Performance

Shares of NASDAQ TNDM opened at $17.06 on Wednesday. The business has a 50-day moving average price of $17.31 and a 200 day moving average price of $18.82. The company has a debt-to-equity ratio of 4.47, a current ratio of 3.20 and a quick ratio of 2.65. Tandem Diabetes Care has a 52-week low of $12.26 and a 52-week high of $29.65.

Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The medical device company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.15. Tandem Diabetes Care had a negative return on equity of 35.61% and a negative net margin of 4.58%. The company had revenue of $283.69 million for the quarter, compared to analyst estimates of $265.85 million. During the same quarter in the previous year, the company posted ($0.31) earnings per share. The firm’s revenue was up 13.8% compared to the same quarter last year. Equities analysts predict that Tandem Diabetes Care will post -0.61 EPS for the current year.

Insider Buying and Selling at Tandem Diabetes Care

In related news, Director Christopher J. Twomey sold 1,700 shares of Tandem Diabetes Care stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $19.15, for a total value of $32,555.00. Following the transaction, the director directly owned 24,434 shares in the company, valued at $467,911.10. This trade represents a 6.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tandem Diabetes Care

A number of large investors have recently bought and sold shares of the company. Integrated Wealth Concepts LLC purchased a new stake in shares of Tandem Diabetes Care in the second quarter valued at approximately $33,000. Sterling Capital Management LLC grew its holdings in Tandem Diabetes Care by 849.0% during the third quarter. Sterling Capital Management LLC now owns 2,325 shares of the medical device company’s stock worth $38,000 after acquiring an additional 2,080 shares during the period. Fulcrum Asset Management LLP grew its holdings in Tandem Diabetes Care by 1,463.6% during the third quarter. Fulcrum Asset Management LLP now owns 4,378 shares of the medical device company’s stock worth $73,000 after acquiring an additional 4,098 shares during the period. Prosperitas Financial LLC purchased a new position in Tandem Diabetes Care in the second quarter worth $151,000. Finally, Provenance Wealth Advisors LLC purchased a new position in Tandem Diabetes Care in the third quarter worth $158,000.

About Tandem Diabetes Care

(Get Free Report)

Tandem Diabetes Care develops and commercializes technology for people who use insulin to manage diabetes. Its products include insulin pumps, infusion sets and related supplies, along with software for viewing and sharing diabetes-management data. The company’s offerings include the t:slim X2 insulin pump and the Tandem Mobi pump, as well as Control-IQ technology, which can automatically adjust insulin delivery based on continuous glucose monitor readings when used with compatible devices. Tandem also provides mobile apps and cloud-based tools to support users and healthcare providers.

See Also

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.